These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 853069)

  • 21. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 22. Counterfeit drugs.
    Rudolf PM; Bernstein IB
    N Engl J Med; 2004 Apr; 350(14):1384-6. PubMed ID: 15070787
    [No Abstract]   [Full Text] [Related]  

  • 23. Secondary wholesalers oppose FDA pedigree regulation.
    Young D
    Am J Health Syst Pharm; 2001 Sep; 58(18):1698, 1700. PubMed ID: 11571811
    [No Abstract]   [Full Text] [Related]  

  • 24. Mutual recognition agreements and harmonization.
    Horton L
    Seton Hall Law Rev; 1998; 29(2):692-735. PubMed ID: 10569828
    [No Abstract]   [Full Text] [Related]  

  • 25. Generally Regarded As Safe.
    Novack GD
    Ocul Surf; 2017 Jan; 15(1):152-155. PubMed ID: 27871773
    [No Abstract]   [Full Text] [Related]  

  • 26. The cosmetic/drug dilemma: FDA regulation of alpha-hydroxy acids.
    Heymann LA
    Food Drug Law J; 1997; 52(4):357-75. PubMed ID: 10346670
    [No Abstract]   [Full Text] [Related]  

  • 27. The Food and Drug Administration's over-the-counter drug review: why review OTC drugs?
    Moxley JH; Yingling GL; Edwards CC
    Fed Proc; 1973 Apr; 32(4):1435-7. PubMed ID: 4701750
    [No Abstract]   [Full Text] [Related]  

  • 28. A "relative efficacy" system for new drugs.
    Stolley PD; Goddard JL
    Ann Intern Med; 1970 Sep; 73(3):479-80. PubMed ID: 5455998
    [No Abstract]   [Full Text] [Related]  

  • 29. Understanding the Food and Drug Administration's Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.
    Thompson BM; Scott BI; Boiani JA
    Clin Lab Med; 2016 Sep; 36(3):575-85. PubMed ID: 27514469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New classification of drugs.
    J Fla Med Assoc; 1972 Jan; 59(1):37. PubMed ID: 5058956
    [No Abstract]   [Full Text] [Related]  

  • 31. US drug shortages are set to reach record high in 2011, report says.
    Tanne JH
    BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406
    [No Abstract]   [Full Text] [Related]  

  • 32. The cosmetic ingredient review self-regulatory safety program.
    Bergfeld WF; Elder RL; Schroeter AL
    Dermatol Clin; 1991 Jan; 9(1):105-22. PubMed ID: 2022088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to the applicability of proposed large volume parenteral regulations to small volume parenteral drug products.
    Bull Parenter Drug Assoc; 1976; 30(6):265-79. PubMed ID: 1000103
    [No Abstract]   [Full Text] [Related]  

  • 34. Preclearance of drug products--pharmacy's perspective.
    Feldmann EG
    Am Pharm; 1981 Jun; NS21(6):26-32. PubMed ID: 7246421
    [No Abstract]   [Full Text] [Related]  

  • 35. The Food and Drug Administration's requirements for approval of new dental drugs.
    Gilkes CC
    Symp Pharmacol Ther Toxicol Group; 1975 Apr; ():5-12. PubMed ID: 1064180
    [No Abstract]   [Full Text] [Related]  

  • 36. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA regulation of drugs, devices.
    Radzius JR
    AORN J; 1976 Aug; 24(2):254-5, 258-9, 262-3. PubMed ID: 1047997
    [No Abstract]   [Full Text] [Related]  

  • 38. Cancer-causing substances in food, drugs, and cosmetics. The de minimis rule versus the Delaney clause.
    Curran WJ
    N Engl J Med; 1988 Nov; 319(19):1262-4. PubMed ID: 3273488
    [No Abstract]   [Full Text] [Related]  

  • 39. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 40. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.